Abstract
Use of antiosteoporotic medication in the population-based, risk-stratified osteoporosis strategy evaluation (ROSE) screening study, comparing the use of FRAX followed by DXA with usual care, was examined. Screening increased the overall use of medication. Being recommended treatment by the hospital and higher age increased the likelihood of starting medication, but, nevertheless, a large percentage opted not to start treatment.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Osteoporosis International |
Sider (fra-til) | 1223-1233 |
ISSN | 0937-941X |
DOI | |
Status | Udgivet - mar. 2019 |
Udgivet eksternt | Ja |